TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29049935
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (IN-OT)
Study: 23698496
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg + bupivacaine 0.5%
Study: 23698496
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 mL + bupivacaine 0.5%
Study: 10863994
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (LS; sodium chloride intake <5 g per day)
Study: 1625504
Drug: Omeprazole-treated patients
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-treated patients re-examined 10 days after drug withdrawal
Study: 3960476
Drug: Topical Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Indomethacin and topical steroid treatment
Study: 3365283
Drug: Alcohol (1
Normalized name: POLYVINYL ALCOHOL (18000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1 g/kg)
Study: 30176632
Drug: Cimicifuga racemosa
Normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifuga racemosa extract BNO 1055 added to standard treatment
Study: 12057714
Drug: Raloxifene, 60
Normalized name: Raloxifene, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene, 60 mg/d for 3 months
Study: 27829454
Drug: 4-week dose
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week dose reduction group (N = 125)
Study: 24088010
Drug: Horse riding
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse riding therapy (six 30-minute sessions)
Study: 10994157
Drug: Oral enzyme
Normalized name: alpha-D-galactosidase enzyme Disintegrating Oral Tablet [Beano]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enzyme combination product (OE; Phlogenzym(®), containing trypsin, bromelain and rutin)
Study: 10994157
Drug: Oral enzyme
Normalized name: alpha-D-galactosidase enzyme Disintegrating Oral Tablet [Beano]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enzyme combination product (OE)
Study: 9312762
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAID)
Study: 8791954
Drug: Amoxycillin 750
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 750 mg b.d. + placebo
Study: 17898099
Drug: Statins treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins treatment with varying HDL cholesterol levels
Study: 355604
Drug: Best conventional
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best conventional care (no chemotherapy or radiotherapy)
Study: 18030066
Drug: Prasugrel 10-mg
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10-mg MD
Study: 8604671
Drug: Oral riboflavin
Normalized name: riboflavin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral riboflavin (60 mg)
Study: 8843991
Drug: Intravenous riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous riboflavin (11.6 mg)
Study: 31221882
Drug: Potent topical
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent topical corticosteroid (TCS) once daily
Study: 19561542
Drug: Infliximab therapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab therapy (3-dose induction regimen)
Study: 11157525
Drug: Nasal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal diamorphine spray
Study: 8451894
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g Cefuroxim (n = 70)
Study: 23948125
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg once daily for 24 weeks
Study: 27733388
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM ketorolac (nonselective COX inhibitor)
Study: 27733388
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM NG‐nitro‐l‐arginine methyl ester (nonselective NOS inhibitor)
Study: 11313839
Drug: sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sertraline
Study: 29273872
Drug: Intravenous lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lansoprazole (30 mg) as a continuous infusion twice daily for 3 days starting the day before ESD, followed by lansoprazole OD tablets (30 mg) orally once daily on days 4-56
Study: 23616513
Drug: Wheat rolls
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat rolls fortified with microencapsulated L-5-methyltetrahydrofolic acid (452 μg/d)
Study: 19728370
Drug: Lenalidomide 5
Normalized name: lenalidomide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 5 mg
Study: 18855269
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day telmisartan
Study: 18559649
Drug: Artemisone 80
Normalized name: Artemisone
DrugBank: Artemisone (DB16097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisone 80 mg (single dose)
Study: 19403270
Drug: Social recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social recovery orientated cognitive behavioural therapy (SRCBT)
Study: 9374251
Drug: Latanoprost 50
Normalized name: Latanoprost 50 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 50 microg/ml, three drops once daily
Study: 3050087
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid 20 mg/week
Study: 8977677
Drug: Tacalcitol ointment
Normalized name: tacalcitol
DrugBank: Tacalcitol (DB13689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacalcitol ointment (4 micrograms/g, once daily for 8 weeks)
Study: 24722960
Drug: 6-month telephone-based
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month telephone-based health coaching intervention (11 sessions using acceptance and commitment therapy strategies)
Study: 6421424
Drug: Beef ultralente
Normalized name: INSULIN BEEF ULTRALENTE 100U/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef ultralente insulin
Study: 3527523
Drug: Human ultralente
Normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human ultralente insulin
Study: 16914369
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg/day
Study: 2212374
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (mean 27.5 mg) administered three times daily for at least 2 weeks
Study: 16860171
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d olanzapine for 20 days (group A, n=12)
Study: 28152989
Drug: SQ-LNS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNS with 0, 5 or 10 mg zinc, 6 mg iron, and 400 μg vitamin A, along with malaria and diarrhea treatment.
Study: 28152989
Drug: SQ-LNS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNS with 10 mg zinc.
Study: 3047214
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg
Study: 9022602
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy in hypertensive women
Study: 15715103
Drug: Radiotherapy in
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy in conjunction with roentgeno‐endovascular occlusion of the internal ileal arteries and/or regional chemotherapy
Study: 17300593
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg q.d. + Pioglitazone 30 mg q.d. (100/30 mg q.d.)
Study: 17300593
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg q.d. (monotherapy)
Study: 10401948
Drug: Inspiratory Pressure
Normalized name: inspiratory pressure threshold loading device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Pressure Support (IPS) > 5 cm H2O in low ventilation group (10 l/min)
Study: 10401948
Drug: Automatic Tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic Tube Compensation (ATC) in high ventilation group (> 10 l/min)
Study: 19255890
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (placebo) capsules
Study: 6528959
Drug: Theo-Dur, 300
Normalized name: Theo-Dur, 300 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur, 300 mg twice daily
Study: 2196145
Drug: Pentoxifylline 200
Normalized name: pentoxifylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 200 mg
Study: 30465175
Drug: Acotiamide 300
Normalized name: acetiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide 300 mg/day for 2 weeks
Study: 24916552
Drug: Sugar equivalent
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar equivalent component in ice cream
Study: 16826054
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (10 MU/0.1 mL saline)
Study: 30576842
Drug: Multi-faceted intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-faceted intervention to improve adherence to P2Y12 inhibitors
Study: 24637559
Drug: Low-dose sildenafil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sildenafil
Study: 11800303
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate 2 mg/kg as the first dose, 1 mg/kg every 12 hours orally for at least 5 days together with split doses of mefloquine, 15 mg/kg and 6 hours later 10 mg/kg orally 1 day after artesunate was stopped (group II)
Study: 2280168
Drug: Irlen filter
Normalized name: FILTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irlen filter treatment group (n = 11)
Study: 26119285
Drug: Cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream with aqueous extract from leaf of five-leaf serratula containing 2.51% of arbutin applied twice a day for 8 weeks
Study: 16443418
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration for 12 hours before contrast exposure, followed by hemofiltration for 18 to 24 hours after contrast exposure (post‐hemofiltration group; n = 31)
Study: 16443418
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration with isotonic saline (1 mL x kg x h for 12 hours before and after contrast exposure, control group; n = 30)
Study: 29362255
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise programme using Physitrack (online exercise prescription tool) for 8 weeks
Study: 17912104
Drug: Biotène Oral
Normalized name: BIOTENE
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotène Oral Balance gel and toothpaste used daily
Study: 23052751
Drug: Enhanced recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced recovery protocols including early laparoscopic cholecystectomy, restrictive endoscopic intervention, and early oral nutrition
Study: 12809836
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg p.o. t.i.d. for 4 weeks
Study: 10397378
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 600 mg clomethiazole edisylate
Study: 10397378
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 600 mg clomethiazole edisylate
Study: 21664710
Drug: Low-dose arms
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose arms (24Gy for indolent NHL and 30Gy for aggressive NHL)
Study: 31740427
Drug: Novel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel treatment (specifics not provided)
Study: 2979691
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg at night
Study: 6441815
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg at night
Study: 1550148
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 in a controlled-release vaginal pessary
Study: 16960155
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin supplementation (5 mg folic acid, 50 mg pyridoxine, and 0.4 mg cyanocobalamin)
Study: 1892032
Drug: Barium sulfate
Normalized name: Barium Sulfate
DrugBank: Barium (DB12481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barium sulfate (600-900 ml orally and 400 ml rectally)
Study: 28797450
Drug: Early tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early tube feeding prior to treatment
Study: 25836351
Drug: 30-month treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-month treatment with fluticasone (500 μg bid)
Study: 16595218
Drug: Luteinizing hormone
Normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone (LH) surge group
Study: 25428566
Drug: Paraffin bath
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin bath therapy with wrist orthosis
Study: 9096989
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg daily, titrated up to 40 mg daily
Study: 19545680
Drug: Cordyceps sinensis
Normalized name: CORDYCEPS SINENSIS
DrugBank: Ophiocordyceps sinensis (DB19288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordyceps sinensis (CS) 1.0 g 3 times a day
Study: 10686270
Drug: Ketamine hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine hydrochloride (.5 mg/kg)
Study: 26156737
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg vitamin D₃/d
Study: 10779419
Drug: BFM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFM treatment with cranial irradiation
Study: 20628590
Drug: Non-ACEi therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ACEi therapy
Study: 30654808
Drug: Artemether (AM)
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether (AM) 1.7 mg/kg and lumefantrine (LUM) 12 mg/kg twice daily for 3 days
Study: 12844250
Drug: Dexamethasone (Dex)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (Dex) 8 mg administered on days 2-4 after chemotherapy
Study: 11783280
Drug: Jiakang Ning
Normalized name: Scrophularia ningpoensis root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiakang Ning (JKN) with low dose Tapazol
Study: 18334909
Drug: Iloperidone 24
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 24 mg/d and Ziprasidone 160 mg/d
Study: 6140699
Drug: Ethanol 0.4
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.4 g/kg
Study: 21670177
Drug: Crushed tablet
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablet
Study: 18811878
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP), 500 microg twice daily
Study: 9026280
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol with GnRH agonist in depot formula
Study: 14997006
Drug: Anakinra therapy
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra therapy
Study: 8008325
Drug: Erythromycin, 500
Normalized name: Erythromycin, 500 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 500 mg orally four times a day for 7 days (initial dosage)
Study: 8008325
Drug: Erythromycin, 250
Normalized name: Erythromycin, 250 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 250 mg orally four times a day (adjusted dosage)
Study: 28093533
Drug: Deworming intervention
Normalized name: oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deworming intervention with 400 mg of albendazole and educational training about STH infection, treatment, and prevention, conducted twice (May 2013 and November 2013)
Study: 26213879
Drug: Analgesic administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic administration with massage
Study: 24721481
Drug: 30-minute computerized
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute computerized brief motivational intervention (C‐BMI) plus access to free nicotine replacement therapy (NRT)
Study: 1957836
Drug: Flavone acetic
Normalized name: flavone
DrugBank: Flavone (DB07776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavone acetic acid (FAA) at 5,120 and 6,144 mg/m2 as 3-hour intravenous infusions
Study: 7223659
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg slow release oxprenolol, once daily
Study: 1107090
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone in a stabilized 10% urea cream
Study: 12048631
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (n = 46)
Study: 8004302
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 15 ppm NO in air
Study: 27197662
Drug: FEX 60
Normalized name: Wal-Fex 60 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEX 60 mg with 150 mL of AJ
Study: 8836275
Drug: Nebulized tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized tetracaine 0.5 mg/kg
Study: 12815350
Drug: 6-degree taper
Normalized name: CAPER BERRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-degree taper
Study: 6666227
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ISDN sustained-release, three times a day
Study: 19597031
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tamoxifen and fenretinide
Study: 1576071
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (1 g three times daily)
Study: 3797019
Drug: Self-efficacy expectancies
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-efficacy expectancies and pain tolerance times at treatment
Study: 31452081
Drug: Extended interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended interval dosing (EID) of natalizumab (MDI 6.2 weeks)
Study: 27449661
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive RRT (hemodialysis or sustained low‐efficiency dialysis six times per week or continuous venovenous hemodiafiltration at 35 ml/kg per hour)
Study: 9299805
Drug: BIGCBT without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIGCBT without medication
Study: 3091405
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (50 mg)
Study: 20949263
Drug: Non-fixed dose
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fixed dose combination (Arsuamoon AS 50 mg and Flavoquine AQ 200 mg)
Study: 31927548
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serum cystatin C (sCysC) and urinary N-Acetyl-Beta-D-glucosaminidase (uNAG)
Study: 9253339
Drug: T4 treatment
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 treatment (L-thyroxine) at a mean dose of 2.8 +/- 0.9 micrograms/kg (0.192 +/- 0.058 mg/day) for a mean duration of 9.2 +/- 5.4 yr
Study: 25398701
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant